Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Stock Information for Calyxt Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Calyxt Inc.

Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025
Cellectis Reports Financial Results for the First Quarter 2025
Cellectis to Report First Quarter Financial Results on May 12, 2025
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.